Abstract
AbstractPhage therapy is a promising strategy to treat antimicrobial-resistant infections. Currently, phage therapy applications span personalised treatments that are tailored for a given patient’s infection, through to the use of pre-established cocktails of virulent phages against clinically relevant pathogens. However, both approaches face challenges, with personalised phage therapy being time-consuming and requiring a phage match to a patient’s infection, while phage cocktails may not be effective against a patient’s specific strain. The Alfred Hospital in Melbourne, Australia has reported an ongoing outbreak of infections by theEnterobacter cloacaecomplex (ECC), a group of emerging multidrug-resistant pathogens responsible for considerable morbidity and mortality. Utilising the hospital’s strain collection, built over the last decade, we established an initial three-phage product with 54% ECC coverage that effectively reduced bacterial loads (>99%) in septicaemic mice. We then iteratively improved this product by enhancing phage killing efficiency using phage training and expanded host range through targeted phage isolation against low-coverage ECC strains. This iterative optimisation led to the creation of the productEntelli-02, containing five well characterised virulent phages that target clinical ECC strains through distinct bacterial cell surface receptors. Importantly,Entelli-02exhibits broad host coverage (99%) and efficacy (92%) against The Alfred Hospital’s ECC strain collection (n= 156). We produced this as a therapeutic-grade product, verified and endotoxin unit compliant, ready for use. This approach integrated academic phage research with clinical insights to produce the phage productEntelli-02as an institution-specific phage cocktail with frontline efficacy and on-demand availability.SUMMARYIn briefWe developed a phage product containing five phages with frontline potential to address infections caused by multidrug-resistantEnterobacter cloacaecomplex.
Publisher
Cold Spring Harbor Laboratory
Reference80 articles.
1. World Health Organization. Addressing the burden of infections and antimicrobial resistance associated with health care focus on G7 countries. (ed. Aaes-Jorgensen, A. ) (WHO, Geneva, Addressing the burden of infections and antimicrobial resistance associated with health care focus on G7 countries 2022).
2. Gordillo Altamirano, F.L. & Barr, J.J. Phage Therapy in the Postantibiotic Era. Clinical microbiology reviews 32(2019).
3. Phage treatment of human infections
4. Phage cocktails and the future of phage therapy
5. Case report: Analysis of phage therapy failure in a patient with a Pseudomonas aeruginosa prosthetic vascular graft infection;Front Med (Lausanne),2023